Longevity investing

Global pandemics & accelerated investment in Longevity

Dmitry Kaminskiy, Co-founder / Managing Partner, Deep Knowledge Ventures / Longevity.Capital / Deep Knowledge Analytics.

The crucial question in Longevity investing: is it repair?

Reason, Co-founder and CEO, Repair Biotechnologies & Fight Aging!

Genome editing: opportunity & anxiety in equal measure

James Lawford Davies, Partner, Hill Dickinson

How to identify new targets and indications for aging drug development

Simon Melov, Professor, Buck Institute and Founder and CEO, Gerostate Alpha

Risk & reward: Longevity investments

Ronjon Nag, Managing Director and Founder, R42 Group

5 investment lessons from coronavirus

Sergey Young, Founder, Longevity Vision Fund.

‘Longevity investing’ Ask Me Anything

Various speakers from the conference come together to answer your questions on Longevity investing.

Latest articles

eGenesis’ xenotransplantation trials move closer to in-human

eGenesis' groundbreaking xenotransplantation work with Massachusetts General Hospital to be expanded through additional collaboration. eGenesis has announced it is expanding its research collaboration with the...

New Japanese stem cell clinical trial for aging frailty

Longeveron announces Phase 2 clinical trial to evaluate the safety and efficacy of Mesenchymal Stem Cells (LMSCs) for the treatment of aging frailty in...

Unlocking the Longevity potential of our oceans

Biologist focuses on the coast of Oman to discover how extreme environments and oceanic life could provide sources for Longevity. With issues like climate change, overfishing...

Alkahest announces phase 2 study treatment of cognitive impairment

Extra-corporeal medical device could improve neuro outlook for end-stage renal disease patients. Alkahest has announced its first foray into dialysis-associated dementia with a new randomised,...